新供者分层策略改善年轻急性白血病患者异基因移植生存:III期随机对照研究
研究纳入430例≤35岁急性白血病患者进行回顾性分析,发现MSD或HSD移植的5年OS优于URD或HPD。高危患者HSD-HSCT较MSD-HSCT复发率更低(p=0.014)、DFS更高(p=0.029)。
要点
- 年轻急性白血病患者中,MSD或HSD移植的5年OS优于URD或HPD。
- 高危患者HSD-HSCT较MSD-HSCT复发率更低、DFS更高。
- 新供者分层策略较传统分层显著改善2年OS和DFS。
核心结论
- 新供者分层策略可为年轻急性白血病患者带来生存优势。
- HSD在部分患者中可替代MSD作为一线供者选择。
主要发现
- MSD或HSD移植患者的5年OS优于URD或HPD移植患者。
- 高危患者HSD-HSCT较MSD-HSCT复发率更低(p=0.014)、DFS更高(p=0.029)。
- 高危患者接受URD或HPD移植的结局相当。
- 中/标危患者MSD或HSD移植结局相当,均可作为一线供者选择。
- URD较HPD非复发死亡率降低、OS和DFS更高。
关键数值与推荐
- 新供者分层组2年OS为76.2%,传统分层组为67.8%(p=0.046)。
- 新供者分层组2年DFS为71.8%,传统分层组为64.5%(p=0.039)。
临床怎么用
- 年轻急性白血病患者选择供者时可优先考虑MSD或HSD。
- 高危患者可优先选择HSD以降低复发、改善DFS。
- 中/标危患者MSD或HSD均可作为一线供者。
- URD宜优先于HPD选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of our study was to evaluate the most optimal donor for young acute leukemia (AL) patients with multiple donors available for allogeneic hematopoietic stem cell transplantation (allo-HSCT), including HLA-matched sibling donors (MSDs), HLA-matched unrelated donors (URDs), haploidentical parental donors (HPDs), and haploidentical sibling donors (HSDs). From March 2008 to December 2016, 430 AL patients ≤ 35 years of age were included in the discovery, retrospective study. Patients who received transplantation from a MSD or a HSD had better 5-year OS rates compared with patients who received transplantation from a URD or a HPD. A superior graft-versus-leukemia effect was observed for high-risk patients undergoing HSD-HSCT with a lower relapse rate (p = 0.014) and a higher disease-free survival (DFS) rate (p = 0.029) compared with those undergoing MSD-HSCT. Outcomes of high-risk patients receiving an URD or HPD were equivalent. For intermediate/standard-risk patients, either a MSD or HSD may be the front-line donor selection with comparable outcomes. HLA-matched unrelated donors were preferred over HPDs with reduced non-relapse mortality and higher overall survival (OS) and DFS rates. We further conducted an independent prospective randomized study to evaluate the survival advantage with the new donor hierarchy. Two hundred and fifty patients were randomly assigned to follow our new donor hierarchy or the traditional donor hierarchy at a 2:1 ratio. The new donor hierarchy contributed to significantly superior 2-year OS and DFS rates (OS: 76.2% vs. 67.8%, p = 0.046; DFS: 71.8% vs. 64.5%, p = 0.039).
引用
- Zhang M, Xiao H, Shi J, et al. Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study. Am J Hematol. 2021. PMID: 34370319. doi:10.1002/ajh.26317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。